Viral Vector and Plasmid DNA Manufacturing Market – Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type (Plasmid DNA, Viral Vector, Non-viral Vector), By Application (Cancer, Genetic Disorder, Infectious Disease, Others), By Region, & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 7.17 Billion
CAGR (2026-2031)	11.03%
Fastest Growing Segment	Cancer
Largest Market	North America
Market Size (2031)	USD 13.43 Billion

Market Overview

The Global Viral Vector and Plasmid DNA Manufacturing Market will grow from USD 7.17 Billion in 2025 to USD 13.43 Billion by 2031 at a 11.03% CAGR. Viral vector and plasmid DNA manufacturing encompasses the specialized production of biological vehicles and genetic templates required for gene therapies and vaccines. The market is propelled by the escalating prevalence of chronic and genetic disorders which drives the need for advanced therapeutic interventions. This expansion is further supported by the substantial number of therapeutic candidates advancing through clinical development phases. According to the American Society of Gene & Cell Therapy, in 2025, the global landscape remained robust with more than 3,200 gene, cell, and RNA therapy trials underway worldwide.

Despite this progress, a significant challenge impeding market expansion is the technical difficulty associated with scaling production to commercial levels. Manufacturers often struggle to maintain consistent quality and high yields when transitioning from laboratory settings to mass production. This manufacturing bottleneck results in supply shortages and prohibitive costs that can delay the availability of critical treatments and restrict the overall growth of the sector.

Key Market Drivers

The exponential growth in gene and cell therapy clinical pipelines serves as the primary catalyst for the Global Viral Vector and Plasmid DNA Manufacturing Market. As therapeutic candidates transition from early-stage research to late-stage clinical trials and commercialization, the demand for high-quality, GMP-grade viral vectors has intensified. This surge is underpinned by substantial capital inflows aimed at accelerating development timelines. According to the Alliance for Regenerative Medicine, January 2025, in the '2025 Cell & Gene State of the Industry Briefing', investment in the sector grew 30% year-over-year to reach $15.2 billion, directly supporting the advancement of these therapeutic programs. This financial backing has led to tangible regulatory successes, further validating the market's potential. According to the International Society for Cell & Gene Therapy, in 2025, regulatory bodies approved seven new cell and gene therapy products in the United States during the preceding year, creating an immediate commercial requirement for scalable vector production.

Increasing reliance on Contract Development and Manufacturing Organizations (CDMOs) is the second major driver, reshaping the supply chain landscape. Biopharmaceutical companies, particularly small to mid-sized innovators, often lack the specialized infrastructure and technical expertise required for complex viral vector production. Consequently, they are aggressively outsourcing manufacturing to CDMOs to mitigate technical risks and expedite time-to-market. This trend is evident in the financial performance of key industry service providers who are expanding capacity to meet this critical need. According to Oxford Biomedica, April 2025, in the 'Preliminary results for the year ended 31 December 2024', the company reported a 44% increase in revenue to £128.8 million, driven largely by the robust demand for lentiviral vector manufacturing services. This shift underscores the pivotal role of contract manufacturers in bridging the gap between clinical innovation and commercial availability.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the Global Viral Vector and Plasmid DNA Manufacturing Market is the technical difficulty associated with scaling production to commercial levels. Unlike traditional pharmaceuticals, viral vectors and plasmid DNA require highly complex biological processes that are sensitive to minor environmental variations. When manufacturers attempt to transition from laboratory-scale efficacy to mass production, they frequently encounter significant drops in yield and consistency. This inability to maintain high-quality output at scale creates a severe bottleneck, restricting the supply of essential genetic material and keeping production costs prohibitively high for many developers.

This manufacturing constraint directly limits the commercial viability of numerous potential therapies. As a result, the market remains heavily concentrated around a small number of successful treatments rather than a broad portfolio of accessible medicines. This disparity is evident in recent industry data which highlights the struggle to commercialize the vast pipeline of clinical candidates. According to the Alliance for Regenerative Medicine, in 2025, approximately 75 percent of global revenue in the advanced therapy sector was generated by fewer than ten commercialized products. This high concentration underscores how scalability hurdles prevent the wider sector from capitalizing on the thousands of therapeutic candidates currently in development.

Key Market Trends

The Integration of Automated and Closed-System Manufacturing is fundamentally reshaping production protocols to overcome chronic scalability and quality control challenges. By transitioning from manual, open operations to fully enclosed, robotic platforms, manufacturers can significantly reduce contamination risks and ensure higher batch-to-batch consistency. This technical evolution is characterized by substantial investments in facilities designed to industrialize complex viral vector processes through digitization and robotics. According to Novartis, February 2025, in the press release 'In Slovenia, Novartis opens its first specialized viral vector production facility in Europe', the company launched a EUR 40 million fully automated manufacturing site, VIFA One, which utilizes advanced robotics to manage all production stages under a single roof.

Simultaneously, the Shift Toward Enzymatic and Synthetic DNA Production represents a critical move away from cell-based plasmid fermentation toward cleaner, cell-free synthesis methods. This technology addresses the limitations of biological variability and long lead times associated with traditional bacterial cultures, offering a streamlined route for generating high-purity genetic starting materials. The accelerating adoption of these synthetic templates is evident in the financial performance of specialized technology providers. According to 4basebio, September 2025, in the 'Half-year Report for the six months ended 30 June 2025', the company announced that strong uptake of its synthetic DNA solutions drove revenue to £1.2 million for the first half of the year, a figure surpassing its total revenue for the entire prior year by 25%.

Segmental Insights

The cancer segment currently represents the fastest-growing application area within the global viral vector and plasmid DNA manufacturing market. This accelerated expansion is primarily driven by the increasing approval and commercialization of gene therapies, such as CAR-T cell treatments, which rely heavily on viral vectors for delivery. Regulatory support from agencies like the US FDA for oncology-focused therapeutics further incentivizes manufacturers to scale production capabilities. Consequently, the rising global prevalence of malignancies fosters a sustained demand for specialized manufacturing services dedicated to developing effective oncological interventions.

Regional Insights

North America holds a dominant position in the global viral vector and plasmid DNA manufacturing market, driven by a high concentration of biopharmaceutical companies and contract manufacturers. The region benefits from substantial investment in gene therapy research and a robust clinical pipeline targeting genetic disorders and cancer. Additionally, the U.S. Food and Drug Administration provides supportive regulatory frameworks that facilitate accelerated development and approval pathways for advanced therapeutic products. This combination of strong industrial infrastructure, continuous financial backing, and regulatory clarity secures the region’s leadership in producing these essential biological materials.

Recent Developments

• In January 2025, Aldevron launched its proprietary Alchemy Cell-Free DNA technology, a significant advancement designed to streamline the production of linear DNA templates for mRNA synthesis. This innovative enzymatic manufacturing process eliminated the need for bacterial cell culture, effectively reducing production timelines by more than 50 percent compared to traditional methods. The technology was introduced to support research-grade applications initially, with plans to expand into clinical-grade manufacturing. By removing host-cell impurities and simplifying the workflow, the new platform aimed to accelerate the development of RNA-based genomic medicines and vaccines for biotechnology and pharmaceutical partners.
• In June 2024, Bionova Scientific announced a strategic expansion into the plasmid DNA manufacturing sector with a capital commitment of $100 million. The company revealed plans to establish a new 100,000-square-foot current Good Manufacturing Practice facility in The Woodlands, Texas, specifically designed for plasmid DNA development and production. This initiative aimed to address the critical shortage of high-quality starting materials for cell and gene therapies. The facility was scheduled to commence operations in early 2025, offering services ranging from research-grade to commercial-scale manufacturing, thereby broadening the company's capabilities beyond its traditional biologics portfolio.
• In June 2024, GenKOre entered into a strategic collaboration with Revvity’s gene delivery division to advance the development of gene therapy treatments for inherited retinal diseases. The partnership focused on combining GenKOre’s proprietary hypercompact CRISPR-Cas12f gene editing platform, known as TaRGET, with Revvity’s specialized adeno-associated virus vectors. This joint effort aimed to create in vivo therapeutic solutions for conditions such as Leber Congenital Amaurosis 10 and Usher Syndrome Type 2A. The collaboration leveraged the unique strengths of both companies to improve the delivery and efficacy of gene editing payloads, addressing significant unmet medical needs in the ophthalmology sector.
• In May 2024, Charles River Laboratories introduced two new technology transfer frameworks, designated as Modular and Fast Track, to enhance its viral vector contract development and manufacturing services. These frameworks were designed to streamline the transition of gene therapy programs to the company’s Center of Excellence in Maryland, potentially reducing transfer timelines to as little as nine months. The Modular approach offered flexibility for complex projects requiring process changes, while the Fast Track option provided a streamlined path for established processes. This initiative aimed to improve supply chain stability and accelerate the commercialization of advanced therapeutic products.

Key Market Players

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

By Product Type	By Application	By Region
Plasmid DNA Viral Vector Non-viral Vector	Cancer Genetic Disorder Infectious Disease Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Viral Vector and Plasmid DNA Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

• Plasmid DNA
• Viral Vector
• Non-viral Vector

• Viral Vector and Plasmid DNA Manufacturing Market, By Application:

• Cancer
• Genetic Disorder
• Infectious Disease
• Others

• Viral Vector and Plasmid DNA Manufacturing Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE